Profound Medical is a medical device company and an innovator in interventional MRI (iMRI) procedures that enable precise, incision-free therapies that improve doctors’ clinical confidence and procedural control as well as patient outcomes. By leveraging real-time MRI guidance, Profound’s technologies are designed to replace uncertainty with clarity across treatment planning, delivery, and confirmation.
TULSA-PRO® is our flagship platform, enabling MRI-guided, incision-free prostate tissue ablation designed for precision and flexibility. The TULSA Procedure™ allows doctors to see, treat, and confirm therapy in real time, supporting personalized treatment strategies across the continuum of prostate care—from whole-gland to subtotal, hemi, multifocal, and focal treatment. This approach enables individualized care for the full spectrum of prostate disease, while minimizing side effects typically associated with surgery or radiation, such as urinary incontinence and erectile dysfunction.
Profound’s Sonalleve® is an MRI-guided therapy that provides a non-surgical treatment option for pain relief of bone metastases, desmoid tumors, and osteoid osteoma, as well as for common gynecologic conditions including uterine fibroids and adenomyosis.
TULSA-PRO is cleared or approved in the United States, Europe, Canada, Saudi Arabia, India, Australia/New Zealand, and the UAE.
Through real-time MRI guidance and data-driven innovation, Profound is advancing the future of MRI-guided therapy—expanding access to precise, personalized, and incision-free treatment options worldwide.
For more information, visit the Profound Medical website.